Evommune (EVMN) Asset Utilization Ratio (2025 - 2026)

Evommune (EVMN) posted quarterly Asset Utilization Ratio of 0.05 for Q1 2026, down 43.46% quarter-over-quarter from 0.08 in Q4 2025.

Evommune (EVMN) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Evommune (EVMN) has reported Asset Utilization Ratio for 2 consecutive years, with 0.05 the latest figure, recorded in Q1 2026.

In Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.05; the TTM figure through Mar 2026 stood at 0.05 (changed N/A YoY), while the FY2025 annual figure was 0.09, changed N/A from the prior year.
Asset Utilization Ratio fell to 0.05 in Q1 2026 per EVMN's latest filing, from 0.08 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.08 in Q4 2025 and bottomed at 0.05 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.38
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.69
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	186.67
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.13
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.90
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.54
10	Evommune	531.53 Mn	330.73 Mn	-	0.03

Download Data